Atrial natriuretic peptide attenuates LPS-induced lung vascular leak: Role of PAK1

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 299, Issue 5, 2010, Pages

  Birukova, Anna A ^a   Xing, Junjie ^a   Fu, Panfeng ^a   Yakubov, Bakhtiyor ^a   Dubrovskyi, Oleksii ^a   Fortune, Jennifer A ^b   Klibanov, Alexander M ^b   Birukov, Konstantin G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Acute lung injury; Cytoskeleton; Permeability; Pulmonary endothelium; Small interfering RNA in vivo

Indexed keywords

ATRIAL NATRIURETIC FACTOR; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; P21 ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL COUNT; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; HISTOPATHOLOGY; INFLAMMATION; LUNG BLOOD VESSEL; LUNG INJURY; LUNG LAVAGE; LUNG VASCULAR LEAK; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BRONCHOALVEOLAR LAVAGE FLUID; CAPILLARY PERMEABILITY; CELL LINE; ENDOTHELIAL CELLS; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P21-ACTIVATED KINASES; RANDOM ALLOCATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78249266624     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00202.2009     Document Type: Article

References (52)

1. Ahluwalia A, MacAllister RJ, Hobbs AJ. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 99: 83-89, 2004.
2. Anand-Srivastava MB. Natriuretic peptide receptor-C signaling and regulation. Peptides 26: 1044-1059, 2005. (Pubitemid 40725375)
3. Baxter GF. The natriuretic peptides. Basic Res Cardiol 99: 71-75, 2004.
4. Birukov KG, Bochkov VN, Birukova AA, Kawkitinarong K, Rios A, Leitner A, Verin AD, Bokoch GM, Leitinger N, Garcia JG. Epoxycyclopentenone-containing oxidized phospholipids restore endothelial barrier function via Cdc42 and Rac. Circ Res 95: 892-901, 2004. (Pubitemid 39435004)
5. Birukova AA, Alekseeva E, Cokic I, Turner CE, Birukov KG. Cross talk between paxillin and Rac is critical for mediation of barrier-protective effects by oxidized phospholipids. Am J Physiol Lung Cell Mol Physiol 295: L593-L602, 2008.
6. Birukova AA, Alekseeva E, Mikaelyan A, Birukov KG. HGF attenuates thrombin-induced permeability in the human pulmonary endothelial cells by Tiam1-mediated activation of the Rac pathway and by Tiam1/Rac-dependent inhibition of the Rho pathway. FASEB J 21: 2776-2786, 2007. (Pubitemid 47372745)
7. Birukova AA, Chatchavalvanich S, Rios A, Kawkitinarong K, Garcia JG, Birukov KG. Differential regulation of pulmonary endothelial monolayer integrity by varying degrees of cyclic stretch. Am J Pathol 168: 1749-1761, 2006.
8. Birukova AA, Cokic I, Moldobaeva N, Birukov KG. Paxillin is involved in the differential regulation of endothelial barrier by HGF and VEGF. Am J Respir Cell Mol Biol 40: 99-107, 2009.
9. Birukova AA, Fu P, Chatchavalvanich S, Burdette D, Oskolkova O, Bochkov VN, Birukov KG. Polar head groups are important for barrier protective effects of oxidized phospholipids on pulmonary endothelium. Am J Physiol Lung Cell Mol Physiol 292: L924-L935, 2007. (Pubitemid 46608239)
10. Birukova AA, Malyukova I, Mikaelyan A, Fu P, Birukov KG. Tiam1 and betaPIX mediate Rac-dependent endothelial barrier protective response to oxidized phospholipids. J Cell Physiol 211: 608-617, 2007. (Pubitemid 46683029)
11. Birukova AA, Zagranichnaya T, Alekseeva E, Bokoch GM, Birukov KG. Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection. J Cell Physiol 215: 715-724, 2008. (Pubitemid 351632693)
12. 2 promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell Res 313: 2504-2520, 2007.
13. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 348: 241-255, 2000.
14. Bogatcheva NV, Verin AD. The role of cytoskeleton in the regulation of vascular endothelial barrier function. Microvasc Res 76: 202-207, 2008.
15. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 72: 743-781, 2003.
16. Borisy GG, Svitkina TM. Actin machinery: pushing the envelope. Curr Opin Cell Biol 12: 104-112, 2000.
17. Dodd-o JM, Hristopoulos ML, Kibler K, Gutkowska J, Mukaddam-Daher S, Gonzalez A, Welsh-Servinsky LE, Pearse DB. The role of natriuretic peptide receptor-A signaling in unilateral lung ischemia-reperfusion injury in the intact mouse. Am J Physiol Lung Cell Mol Physiol 294: L714-L723, 2008. (Pubitemid 351520104)
18. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330: 625, 2005. (Pubitemid 40444756)
19. Fu P, Birukova AA, Xing J, Sammani S, Murley JS, Garcia JG, Grdina DJ, Birukov KG. Amifostine reduces lung vascular permeability via suppression of inflammatory signalling. Eur Respir J 33: 612-624, 2009.
20. Furst R, Brueckl C, Kuebler WM, Zahler S, Krotz F, Gorlach A, Vollmar AM, Kiemer AK. Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96: 43-53, 2005. (Pubitemid 40095753)
21. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, Gerthoffer WT, Bamberg JR, English D. Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689-701, 2001. (Pubitemid 32906197)
22. Hollister AS, Rodeheffer RJ, White FJ, Potts JR, Imada T, Inagami T. Clearance of atrial natriuretic factor by lung, liver, and kidney in human subjects and the dog. J Clin Invest 83: 623-628, 1989. (Pubitemid 19061186)
23. Irwin DC, Rhodes J, Baker DC, Nelson SE, Tucker A. Atrial natriuretic peptide blockade exacerbates high altitude pulmonary edema in endotoxin-primed rats. High Alt Med Biol 2: 349-360, 2001. (Pubitemid 33100442)
24. Irwin DC, Tissot van Patot MC, Tucker A, Bowen R. Direct ANP inhibition of hypoxia-induced inflammatory pathways in pulmonary microvascular and macrovascular endothelial monolayers. Am J Physiol Lung Cell Mol Physiol 288: L849-L859, 2005. (Pubitemid 40547910)
25. Karmpaliotis D, Kirtane AJ, Ruisi CP, Polonsky T, Malhotra A, Talmor D, Kosmidou I, Jarolim P, de Lemos JA, Sabatine MS, Gibson CM, Morrow D. Diagnostic and prognostic utility of brain natriuretic peptide in subjects admitted to the ICU with hypoxic respiratory failure due to noncardiogenic and cardiogenic pulmonary edema. Chest 131: 964-971, 2007.
26. Ke Y, Lum H, Solaro RJ. Inhibition of endothelial barrier dysfunction by P21-activated kinase-1. Can J Physiol Pharmacol 85: 281-288, 2007.
27. Kiemer AK, Weber NC, Furst R, Bildner N, Kulhanek-Heinze S, Vollmar AM. Inhibition of p38 MAPK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-alpha-induced actin polymerization and endothelial permeability. Circ Res 90: 874-881, 2002.
28. Klinger JR, Warburton R, Carino GP, Murray J, Murphy C, Napier M, Harrington EO. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells. Exp Cell Res 312: 401-410, 2006.
29. Kokot F, Klimek D, Wiecek A, Kuczera M. Atrial natriuretic peptide and arginine-vasopressin secretion in patients with active renal stone disease. Int Urol Nephrol 30: 357-365, 1998.
30. Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, Vollmar AM. Atrial natriuretic peptide, a regulator of nuclear factor-kappaB activation in vivo. Endocrinology 148: 332-336, 2007.
31. Liu F, Schaphorst KL, Verin AD, Jacobs K, Birukova A, Day RM, Bogatcheva N, Bottaro DP, Garcia JG. Hepatocyte growth factor enhances endothelial cell barrier function and cortical cytoskeletal rearrangement: potential role of glycogen synthase kinase-3beta. FASEB J 16: 950-962, 2002.
32. Lofton CE, Baron DA, Heffner JE, Currie MG, Newman WH. Atrial natriuretic peptide inhibits oxidant-induced increases in endothelial permeability. J Mol Cell Cardiol 23: 919-927, 1991.
33. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 86: 279-367, 2006.
34. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaha K. Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 114: 223-228, 1998.
35. Moitra J, Sammani S, Garcia JG. Re-evaluation of Evans Blue dye as a marker of albumin clearance in murine models of acute lung injury. Transl Res 150: 253-265, 2007.
36. Moldobaeva A, Welsh-Servinsky LE, Shimoda LA, Stephens RS, Verin AD, Tuder RM, Pearse DB. Role of protein kinase G in barrier-protective effects of cGMP in human pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 290: L919-L930, 2006.
37. Murohara T, Kugiyama K, Ota Y, Doi H, Ogata N, Ohgushi M, Yasue H. Effects of atrial and brain natriuretic peptides on lysophosphatidylcholine- mediated endothelial dysfunction. J Cardiovasc Pharmacol 34: 870-878, 1999.
38. Nonas S, Birukova AA, Fu P, Xing J, Chatchavalvanich S, Bochkov VN, Leitinger N, Garcia JG, Birukov KG. Oxidized phospholipids reduce ventilator-induced vascular leak and inflammation in vivo. Crit Care 12: R27, 2008.
39. Nonas SA, Miller I, Kawkitinarong K, Chatchavalvanich S, Gorshkova I, Bochkov VN, Leitinger N, Natarajan V, Garcia JG, Birukov KG. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med 173: 1130-1138, 2006.
40. Onuoha GN, Alpar EK, Gowar J. Plasma levels of atrial natriuretic peptide in severe burn injury. Burns 26: 449-453, 2000.
41. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
42. Potter LR. Domain analysis of human transmembrane guanylyl cyclase receptors: implications for regulation. Front Biosci 10: 1205-1220, 2005.
43. Rana R, Vlahakis NE, Daniels CE, Jaffe AS, Klee GG, Hubmayr RD, Gajic O. B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med 34: 1941-1946, 2006.
44. Rentsendorj O, Mirzapoiazova T, Adyshev D, Servinsky LE, Renne T, Verin AD, Pearse DB. Role of vasodilator-stimulated phosphoprotein in cGMP-mediated protection of human pulmonary artery endothelial barrier function. Am J Physiol Lung Cell Mol Physiol 294: L686-L697, 2008.
45. Singleton PA, Chatchavalvanich S, Fu P, Xing J, Birukova AA, Fortune JA, Klibanov AM, Garcia JG, Birukov KG. Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched microdomains regulates endothelial barrier enhancement by oxidized phospholipids. Circ Res 104: 978-986, 2009.
46. Stockton R, Reutershan J, Scott D, Sanders J, Ley K, Schwartz MA. Induction of vascular permeability: beta PIX and GIT1 scaffold the activation of extracellular signal-regulated kinase by PAK. Mol Biol Cell 18: 2346-2355, 2007.
47. Stockton RA, Schaefer E, Schwartz MA. p21-Activated kinase regulates endothelial permeability through modulation of contractility. J Biol Chem 279: 46621-46630, 2004.
48. Thomas M, Ge Q, Lu JJ, Chen J, Klibanov AM. Cross-linked small polyethylenimines: while still nontoxic, deliver DNA efficiently to mammalian cells in vitro and in vivo. Pharm Res 22: 373-380, 2005.
49. Thomas M, Lu JJ, Ge Q, Zhang C, Chen J, Klibanov AM. Full deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung. Proc Natl Acad Sci USA 102: 5679-5684, 2005.
50. Ueda S, Nishio K, Akai Y, Fukushima H, Ueyama T, Kawai Y, Masui K, Yoshioka A, Okuchi K. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Shock 26: 134-139, 2006.
51. Wakabayashi G, Ueda M, Aikawa N, Naruse M, Abe O. Release of ANP and its physiological role in pulmonary injury due to HCl. Am J Physiol Regul Integr Comp Physiol 258: R690-R696, 1990.
52. Weed SA, Parsons JT. Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene 20: 6418-6434, 2001.